canakinumab
Ilaris
Pharmaceutical company: Novartis Pharmaceuticals Corporation
NEW INDICATION & DOSAGE
Gout flares when NSAIDs and colchicine are contraindicated, are not tolerated, or don't provide an adequate response, and when repeated courses of corticosteroids are not appropriate
Adults: 150 mg subcut as a single dose. May re-treat after at least 12 weeks.
Released: November 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
dabrafenib mesylate
Tafinlar
Pharmaceutical company: Novartis Pharmaceuticals Corporation
NEW INDICATION & DOSAGE
Unresectable or metastatic solid tumors with BRAF V600E mutation in patients who have progressed after prior therapy and have no satisfactory alternative treatment options, in combination with trametinib
Children ages 1 to 17 weighing 51 kg or more: 150 mg (as capsules or oral suspension) PO b.i.d.
Children ages 1 to 17 weighing 38 to 50 kg: 100 mg (as capsules) PO b.i.d.
Children ages 1 to 17 weighing at least 26 to 37 kg: 75 mg (as capsules) PO b.i.d.
Children ages 1 to 17 weighing 8 to 50 kg: 20 to 130 mg (as oral suspension) PO b.i.d. based on body weight. See the manufacturer's instructions for recommended dosage table.
Adjust-a-dose: Refer to the trametinib prescribing information for recommended trametinib dosing information. Refer to the manufacturer's instructions for toxicity-related dose adjustments. Continue treatment until disease progression or unacceptable toxicity occurs.
Released: November 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
luspatercept-aamt
Reblozyl
Pharmaceutical company: Bristol-Myers Squibb
NEW INDICATION & DOSAGE
Anemia in patients with very-low-risk to intermediate-risk myelodysplastic syndromes who may require RBC transfusions and who are erythropoiesis-stimulating-agent naïve
Adults: 1 mg/kg subcut once every 3 weeks. Maximum dose, 1.75 mg/kg.
Released: November 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer
trametinib dimethyl sulfoxide
Mekinist
Pharmaceutical company: Novartis Pharmaceuticals Corporation
NEW INDICATION & DOSAGE
Unresectable or metastatic solid tumors with BRAF V600E mutation in patients who have progressed after prior therapy and have no satisfactory alternative treatment options, in combination with dabrafenib
Children ages 1 to 17 weighing 51 kg or more: 2 mg (as tablets or oral solution) PO daily.
Children ages 1 to 17 weighing 38 to 50 kg: 1.5 mg (as tablets) PO once daily.
Children ages 1 to 17 weighing at least 26 to 37 kg: 1 mg (as tablets) PO once daily.
Children ages 1 to 17 weighing 8 to 50 kg: 0.3 to 1.6 mg (as oral solution) PO daily based on body weight. See the manufacturer's instructions for recommended dosage table.
Adjust-a-dose: Refer to the dabrafenib prescribing information for recommended dabrafenib dosing information. Refer to the manufacturer's instructions for toxicity-related dose adjustments. Continue treatment until disease progression or unacceptable toxicity occurs.
Released: November 2023
Nursing Drug Handbook
© 2023 Wolters Kluwer